Serotonin 1A Receptor Binding of [11C]CUMI-101 in Bipolar Depression Quantified Using Positron Emission Tomography: Relationship to Psychopathology and Antidepressant Response.
Serotonin 1A Receptor Binding of [11C]CUMI-101 in Bipolar Depression Quantified Using Positron Emission Tomography: Relationship to Psychopathology and Antidepressant Response.
复制标题
双相抑郁症患者血清素1A受体结合[11C]CUMI-101：与精神病理和抗抑郁反应的关系
DOI：
10.1093/ijnp/pyac001
复制
发表时间：
2022-08-04
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
双相情感障碍（BD）的病理生理学仍然在很大程度上是未知的，尽管它会导致显着的残疾和自杀风险。血清素信号可能在病理生理学中起作用，但缺乏直接证据。抑郁症的治疗是有限的。先前的研究表明，5-羟色胺1A受体（5 HT 1AR）的正电子发射断层扫描（PET）成像可以预测抗抑郁反应。共有20名患有BD的参与者在当前的重度抑郁发作和16名健康志愿者进行了PET成像与[11 C]碘化银-101，采用代谢物校正的输入函数的结合潜力的量化5 HT 1AR。双相情感障碍的参与者随后接受了一项开放标签的为期6周的临床试验，除了他们的情绪稳定剂外，还使用了选择性5-羟色胺再摄取抑制剂（SSRI）。在基线和SSRI治疗期间获得临床评级。[11 C]碘化银-101的治疗前结合潜力（BPF）与BD受试者中的许多治疗前临床变量相关。在中缝核内，它与基线蒙哥马利斯伯格评定量表（P = 0.026）、贝克抑郁量表评分（P = 0.0023）和巴斯杜基敌意指数（P = 0.0058）呈负相关，巴斯杜基敌意指数是一种衡量终生攻击性的指标。二次分析发现，双相情感障碍患者的[11 C] TBI-101 BPF高于健康志愿者（P = 0.00275）。[11 C] TBI-101 BPF在SSRI应答者和非应答者之间没有差异（P = .907），并且不能预测抗抑郁反应（P = .580）。逐体素分析证实了在感兴趣区域分析中获得的结果。5-羟色胺系统功能障碍与BD的诊断及其抑郁症的严重程度相关。治疗前5 HT 1AR结合不能预测SSRI抗抑郁药的疗效。该研究在clinicaltrials.gov上列出，标识符为NCT 02473250。
The pathophysiology of bipolar disorder (BD) remains largely unknown despite it causing significant disability and suicide risk. Serotonin signaling may play a role in the pathophysiology, but direct evidence for this is lacking. Treatment of the depressed phase of the disorder is limited. Previous studies have indicated that positron emission tomography (PET) imaging of the serotonin 1A receptor (5HT1AR) may predict antidepressant response. A total of 20 participants with BD in a current major depressive episode and 16 healthy volunteers had PET imaging with [11C]CUMI-101, employing a metabolite-corrected input function for quantification of binding potential to the 5HT1AR. Bipolar participants then received an open-labeled, 6-week clinical trial with a selective serotonin reuptake inhibitor (SSRI) in addition to their mood stabilizer. Clinical ratings were obtained at baseline and during SSRI treatment. Pretreatment binding potential (BPF) of [11C]CUMI-101 was associated with a number of pretreatment clinical variables within BD participants. Within the raphe nucleus, it was inversely associated with the baseline Montgomery Åsberg Rating Scale (P = .026), the Beck Depression Inventory score (P = .0023), and the Buss Durkee Hostility Index (P = .0058), a measure of lifetime aggression. A secondary analysis found [11C]CUMI-101 BPF was higher in bipolar participants compared with healthy volunteers (P = .00275). [11C]CUMI-101 BPF did not differ between SSRI responders and non-responders (P = .907) to treatment and did not predict antidepressant response (P = .580). Voxel-wise analyses confirmed the results obtained in regions of interest analyses. A disturbance of serotonin system function is associated with both the diagnosis of BD and its severity of depression. Pretreatment 5HT1AR binding did not predict SSRI antidepressant outcome. The study was listed on clinicaltrials.gov with identifier NCT02473250.
登录
查看更多内容
影响因子：
5.7
作者：
Aznavour, Nicolas;Rbah, Latifa;Zimmer, Luc
通讯作者：
Zimmer, Luc
影响因子：
5.4
作者：
Amsterdam, JD;Shults, J;Hundert, M
通讯作者：
Hundert, M
影响因子：
10.6
作者：
Gray, Neil A.;Milak, Matthew S.;DeLorenzo, Christine;Ogden, R. Todd;Huang, Yung-yu;Mann, J. John;Parsey, Ramin V.
通讯作者：
Parsey, Ramin V.
影响因子：
3.8
作者：
Baldessarini, Ross J.;Leahy, Leslie;Hennen, John
通讯作者：
Hennen, John
影响因子：
4
作者：
Khalsa, Hari-Mandir K.;Baldessarini, Ross J.;Salvatore, Paola
通讯作者：
Salvatore, Paola